TMSB10 and glioblastoma: To further explore the therapeutic efficacy of knocking down TMSB10 in combination with selumetinib and PD1 inhibitor treatment for GBM, we generated a patient-derived glioblastoma organoid (GBO) that maintained the heterogeneity of cell types (including macrophages, T cells, and vascular cells) and the molecular characteristics of their respective parental tumors [33] as a model for holistic study of the TME of tumors and evaluating the efficacy of PD1 inhibitors [34, 35].